Murray T J, Kelly P, Campbell L, Stefanik K
Br J Psychiatry. 1977 Apr;130:370-3. doi: 10.1192/bjp.130.4.370.
Haloperidol treatment for stuttering was examined in a double-blind cross-over study of 26 adult volunteers with long-standing stuttering. Most had had unsuccessful speech and drug therapy. During the three-month study, their speech and stuttering patterns were repeatedly evaluated from videotaped readings of a standard passage and during spontaneous speaking. Of the 18 patients completing the trial 11 were significantly more improved on haloperidol than on placebo, three benefited equally from both, and four were unchanged. Improvement over placebo was indicated by fewer dysfluencies, increased speed of speaking, and reduced secondary "struggle" phenomena. Side effects were common on a dosage of 3 mg haloperidol daily. Poor concentration, akathisia and dystonic movements caused 8 patients to discontinue the trial despite significant improvement in 5 of them. Although "statistically significant" improvement occurred in most patients on haloperidol, the "clinical significance" of this form of therapy will be limited by the partial response, the need for continuous medication, the side effects of haloperidol and the attitude of stutters to this type of therapy.
在一项针对26名患有长期口吃的成年志愿者的双盲交叉研究中，研究了氟哌啶醇对口吃的治疗效果。大多数人曾接受过不成功的言语和药物治疗。在为期三个月的研究中，通过对一篇标准文章的录像朗读以及自发讲话过程，反复评估他们的言语和口吃模式。在完成试验的18名患者中，11名服用氟哌啶醇的改善程度明显高于服用安慰剂的，3名从两者中获益相同，4名没有变化。与安慰剂相比，改善表现为言语不流畅减少、说话速度加快以及继发性“挣扎”现象减少。每日服用3毫克氟哌啶醇时副作用很常见。注意力不集中、静坐不能和张力障碍性运动导致8名患者中断试验，尽管其中5名患者有显著改善。虽然大多数服用氟哌啶醇的患者出现了“统计学上显著的”改善，但这种治疗方式的“临床意义”将受到部分反应、持续用药的必要性、氟哌啶醇的副作用以及口吃者对这种治疗类型的态度的限制。
